This site is intended for healthcare professionals only

New perspectives in the multidisciplinary management of stroke associated with diabetes

Webcast

An interactive searchable webcast, from the symposium session at ESOC 2021, featuring polling questions and extra bonus features. Click the image below to begin.

Learning Objectives

After participating in this program learners will be able to:

  • Describe the acute management of hyperglycemia after stroke and benefits of newer antidiabetic agents in stoke prevention
  • Integrate antidiabetic agents into individualized management plans for patients following, or at risk of, a stroke who have concomitant diabetes
  • Discuss how to improve MDT collaboration to enhance outcomes and reduce the burden for patients with diabetes and stroke

Faculty and Disclosures

  • Geert Jan Biessels
  • Blanca Fuentes
  • Hertzel C. Gerstein
  • Stewart B. Harris

Geert Jan Biessels – Program Director

UMC Utrecht Brain Center, Utrecht, The Netherlands

Geert Jan Biessels obtained his PhD in 1997 at Utrecht University, registered as a neurologist in 2004, and was appointed Professor of Cerebrovascular Disease and Cognition in 2012. His area of expertise is vascular cognitive impairment (VCI) and small vessel disease (SVD), focusing on novel imaging markers to improve diagnosis and prognostication and to identify targets for personalized treatment and the role of diabetes.

Professor Biessels is actively involved in several national and international VCI and SVD research networks, including STRIVE and HARNESS. He leads the Dutch Heart Brain Connection consortium and the international Meta VCI Map consortium (https://metavcimap.org/). He was Principal Investigator in two large randomized controlled trials  in diabetes with cognitive outcomes. He participates in the H2020 programs SVDs@target and Recognised.

Professor Biessels has mentored over 40 PhD students and has over 350 peer-reviewed publications. He is a Dutch Research Council Vidi and Vici laureate and received the senior investigator award of the European Stroke Organisation in 2015.

In 2019 and 2020 he served as member of the ESOC Scientific Abstracts Committee. In 2021 and 2022 he had the honour to serve on the ESOC Program Committee.

Disclosures

Consults for Eli Lilly and receives research support from Boehringer Ingelheim. All financial compensation for these services is transferred to his employer, the UMCU.

Blanca Fuentes – Speaker

La Paz University Hospital, Madrid, Spain

Dr Fuentes’ current position is Stroke Unit Division Head at the Department of Neurology and Stroke Unit of La Paz University Hospital Madrid, Spain and Associate Professor (Department of Medicine), School of Medicine, Universidad Autónoma de Madrid, Spain.

Dr Fuentes has been a Fellow of the ESO since November 2016 and is a researcher at the Neurosciences Area of the IdiPAZ Health Research Institute. She has been a member of the Madrid Stroke Network and of the advisory board of the Madrid Health Government for the development and follow-up of the Madrid Stroke Plan since 2014. She has been author of the European Stroke Organisation Guidelines for the management of glucose in acute stroke patients (Eur J Stroke 2018) and of the Spanish Society of Neurology recommendations for stroke prevention in patients with diabetes.

Dr Fuentes research is focused on the treatment of acute stroke, the prognostic influence of hyperglycaemia and diabetes in acute stroke, the development of efficient acute stroke models and stroke prevention. She has a specific interest in translational research in stroke and has been a member of the research team at the Cerebrovascular Diseases and Neurosciences Research Laboratory at the IdiPAZ Health Research Institute, where she has collaborated in the development of preclinical and clinical trials on brain repair therapies.

Disclosures

Honoraria or consultation fees: Novo Nordisk, BMS-Pfizer

Hertzel C. Gerstein – Speaker

McMaster University, Hamilton, Ontario, Canada

Dr Hertzel C. Gerstein is a Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Research Institute Chair in Diabetes and is Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute.

Dr Gerstein’s research has been published in over 400 papers, spans 50 countries and has been funded by the NIH, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, the Canadian Diabetes Association and the pharmaceutical industry. His research focuses on five key areas: a) the prevention and therapy of diabetes and its many consequences; b) the relationship between dysglycemia (a term he coined in 1995), cardiovascular outcomes, cognitive impairment, other diabetes-related chronic consequences and new diabetes; c) strategies for type 2 diabetes remission; d) novel biomarkers for cardiovascular disease in diabetes; and e) the biologic basis of glucose-related health consequences. In 2016 he produced and distributed a music video to mitigate the impact of diabetes on affected people and their families. In 2012 he received the Canadian Diabetes Association’s Lifetime Achievement Award.

Disclosures

Grants/research support: Eli Lilly, Astra Zeneca, Sanofi, Merck, Novo Nordisk; Honoraria or consultation fees: Eli Lilly, Boehringer Ingleheim, Sanofi, Novo Nordisk, Abbott, Pfizer, COVANCE, Kowa, DKSH, Zuellig

Stewart B. Harris – Speaker

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

Professor Stewart Harris holds the Diabetes Canada Chair in Diabetes Management. His research career has focused on identifying and closing the care gap for disadvantaged Canadians with diabetes. His pioneering work carved new understandings of the pathophysiology and epidemiology of diabetes in Canada’s Indigenous Peoples. His research has also had widespread impacts on therapeutic development and management in primary care. His other areas of interest include the epidemiology of hypoglyemcia and pragmatic clinical trials.

He has received numerous awards for his work including being appointed to the Order of Canada in 2015 for his contributions to developing diabetes prevention strategies in Indigenous communities and other vulnerable populations. He has published over 280 articles. Dr. Harris’s internationally recognized career reflects a passionate commitment to medicine, science, and mentorship.

Disclosures

Grants/research support: Abbott, Applied Therapeutics Inc., AstraZeneca, Canadian Institutes for Health Research (CIHR), Eli Lilly, Health Canada/First Nations and Inuit Health Branch, Janssen, Juvenile Diabetes Research Foundation (JDRF), Novo Nordisk, Sanofi, The Lawson Foundation; Honoraria or consultation fees: Abbott, AstraZeneca, Bayer Inc., Eli Lilly, HLS Therapeutics, Janssen, Novo Nordisk, Sanofi

Funding

This program has been made possible with an educational grant from Novo Nordisk A/S.

Contact Us

Email: IME@springer.com

Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK